SELL and neoplasm: As observed in the 4T1 tumour model, treatment with P@aPDL1 and Vadimezan caused approximately a 1.5-fold increase of CD3+ T cells in the PB (Fig. 5f and Supplementary Figs. 13, 14), increase in CD8+ T cells, central memory CD8+ T cells (CD8+CD62L+CD44+), effector memory CD8 T cells (CD8+CD62L−CD44+) and naïve CD8 T cells (CD8+CD62L+CD44−) (Fig. 5g–j).